Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

O'Brien DA, Kaye SM, Poppas PJ, Mahase SS, An A, Christos PJ, et al. Time to administration of stereotactic radiosurgery to the cavity after surgery for brain metastases: a real-world analysis. J Neurosurg. 2021:1-11.

Beg S, Bareja R, Ohara K, Eng KW, Wilkes DC, Pisapia DJ, et al. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Transl Oncol. 2021;14(1):100944.

Vertesich K, Sosa BR, Niu Y, Ji G, Suhardi V, Turajane K, et al. Alendronate enhances osseointegration in a murine implant model. J Orthop Res. 2021;39(4):719-726.

Moon CS, Reglero C, Cortes JR, S Quinn A, Alvarez S, Zhao J, et al. induces NF-κB signaling-driven peripheral T cell lymphoma. Nat Cancer. 2021;2(1):98-113.

Kumar A, Magro C, Lukin DJ. Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease. Gastroenterology. 2021;160(3):e3-e5.

Karafin MS, Becker JL, Berg M, DeSimone RA, Draper NL, Hudgins J, et al. Heterogeneity in Approaches for Switching From Universal to Patient ABO Type-Specific Blood Components During Massive Hemorrhage: An International Survey and Review of the Literature. Arch Pathol Lab Med. 2021.

Ketas TJ, Chaturbhuj D, Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134.

Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, et al. A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion. J Magn Reson Imaging. 2021;54(2):462-471.

Kamboj M, McMillen T, Syed M, Chow HY, Jani K, Aslam A, et al. Evaluation of a Combined Multilocus Sequence Typing and Whole-Genome Sequencing Two-Step Algorithm for Routine Typing of . J Clin Microbiol. 2021;59(2).

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.